CRISPR Therapeutics AG (CRSP) Price to Sales (2016 - 2026)

CRISPR Therapeutics AG has disclosed Price to Sales across 11 years of filings, most recently posting 517.82 for Q2 2026.

• In Q2 2026, Price to Sales fell 89.25% year-over-year to 517.82; the TTM figure through Jun 2026 stood at 393.66 (up 248.45% YoY), while the FY2025 annual figure was 1432.68, up 1484.06% from the prior year.
• Price to Sales came in at 517.82 for Q2 2026 at CRISPR Therapeutics AG, down from 3144.76 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 531921.87 in Q4 2022 to a low of 24.9 in Q4 2023.
• Average Price to Sales over 5 years is 39599.29, with a median of 5167.6 recorded in 2022.
• Year-over-year, Price to Sales jumped 218709.89% in 2022 and plunged 100.0% in 2023.
• Over 5 years, Price to Sales stood at 531921.87 in 2022, then plunged by 100.0% to 24.9 in 2023, then surged by 279.69% to 94.56 in 2024, then soared by 6055.34% to 5820.25 in 2025, then plunged by 91.1% to 517.82 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 517.82 in Q2 2026, 3144.76 in Q1 2026, and 5820.25 in Q4 2025.